Alinidine (CAS 33178-86-8)
QUICK LINKS
Alinidine is a chemical compound that functions as a selective and potent inhibitor of the inward rectifier potassium current in cardiac cells. It achieves this by binding to and blocking the specific channels responsible for the inward rectifier potassium current, thereby reducing the flow of potassium ions across the cell membrane during the repolarization phase of the cardiac action potential. This action results in a prolongation of the action potential duration and an increase in the effective refractory period of the cardiac cells. Its mechanism of action at the molecular level provides insights into the physiological processes involved in cardiac electrophysiology, offering researchers the opportunity to investigate the role of inward rectifier potassium currents in normal and pathological cardiac function.
Alinidine (CAS 33178-86-8) References
- Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. | Zheng, W., et al. 1999. Circ Res. 85: 192-8. PMID: 10417401
- Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies. | Rustenbeck, I., et al. 2001. Biochem Pharmacol. 62: 1695-703. PMID: 11755123
- International Union of Pharmacology. XLII. Compendium of voltage-gated ion channels: cyclic nucleotide-modulated channels. | Hofmann, F., et al. 2003. Pharmacol Rev. 55: 587-9. PMID: 14657416
- Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues. | Rustenbeck, I., et al. 2004. Biochem Pharmacol. 67: 1733-41. PMID: 15081872
- Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. | Dedkov, EI., et al. 2005. Am J Physiol Heart Circ Physiol. 288: H2684-93. PMID: 15681710
- Angiogenesis in ischaemic and hypertrophic hearts induced by long-term bradycardia. | Brown, MD., et al. 2005. Angiogenesis. 8: 253-62. PMID: 16308735
- Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels. | Szollosi, A., et al. 2010. Br J Pharmacol. 159: 669-77. PMID: 20128805
- If Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies. | Mengesha, HG., et al. 2017. Front Pharmacol. 8: 874. PMID: 29225577
- Characterization of drug binding within the HCN1 channel pore. | Tanguay, J., et al. 2019. Sci Rep. 9: 465. PMID: 30679654
- Capillaries as a Therapeutic Target for Heart Failure. | Yoshida, Y., et al. 2022. J Atheroscler Thromb. 29: 971-988. PMID: 35370224
- Cardiac electrophysiologic effects of alinidine, a specific bradycardic agent, in the conscious dog: plasma concentration-response relations. | Boucher, M., et al. 1995. J Cardiovasc Pharmacol. 25: 229-33. PMID: 7752648
- Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. | Aidonidis, I., et al. 1995. Cardiovasc Drugs Ther. 9: 555-63. PMID: 8547205
- Cardiac electrophysiological effects of falipamil in the conscious dog: comparison with alinidine. | Boucher, M., et al. 1996. Eur J Pharmacol. 306: 93-8. PMID: 8813620
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Alinidine, 10 mg | sc-252357 | 10 mg | $100.00 | |||
Alinidine, 100 mg | sc-252357A | 100 mg | $612.00 |